Investor Relations

Delivering value to our shareholders with utmost transparency and timely information.

At Mega Lifesciences public company limited

Investor Relations is responsible for delivering value to our shareholders by communicating all the necessary information on a regular basis.

Investment Highlights

Market leading own consumer health and pharmaceutical brands in fast growing developing markets.

FINANCIAL PERFORMANCE IN 1H23

Overall operating revenue
THB mn
(down by 0.4% YoY)
Gross profit
THB mn
representing 44.7% of operating revenue
SG&A expenses
THB mn
representing 26.8% of operating revenue
Adjusted net profit
THB mn
(down by 0.9% YoY)
Reported net profit
THB mn
(down by 16.8% YoY)

Latest Documents

Read our recent and archived releases, Financial statements, Quarterly results, Presentations, Publications and One Reports.

Financial Statement
Quarter 2/2023
Download
MD&A
Quarter 2/2023
Download
Presentation and Webcast
Investor Presentation 1H/2023
Download
Form 56-1 One Report
Form 56-1 One Report 2022
Download
Resource Center

SET Announcements

11 August 2023
Interim dividend payment 2023
Read More
11 August 2023
Management Discussion and Analysis Quarter 2 Ending 30 Jun 2023
Read More
11 August 2023
Financial Performance Quarter 2 (F45) (Reviewed)
Read More

IR Calendar

13
Nov
2023
3Q23 earnings announcement

IR CONTACT

  • Mr. Manoj Gurbuxani (Primary contact)
  • Mr. Francis Rego
  • Ms. Sujintana Boonworapat
  • Ms. Laila Mitnoi (IR Co-ordinator)
  • Mr. Thomas Abraham
  • Mr. Vivek Dhawan
  • investor@megawecare.com
  • +66 2 769 4230